U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
ORION CORPORATION PRESS RELEASE 8 August 2022 at 9:30 EESTÂ Â Â Â Â Â Â Â Â Â Â Â Â U.S. FDA…